Impact of the International Prognostic Scoring System cytogenetic risk groups on the outcome of patients with primary myelodysplastic syndromes undergoing allogeneic stem cell transplantation from human leukocyte antigen-identical siblings: a retrospective analysis of the European Society for Blood and Marrow Transplantation-Chronic Malignancies Working Party
Francesco Onida,
Ronald Brand,
Anja van Biezen,
Michel Schaap,
Peter A. von dem Borne,
Johan Maertens,
Dietrich W. Beelen,
Enric Carreras,
Emilio P. Alessandrino,
Liisa Volin,
Jürgen H.E. Kuball,
Angela Figuera,
Jorge Sierra,
Jürgen Finke,
Nicolaus Kröger,
Theo de Witte
Affiliations
Francesco Onida
Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico and University of Milan, Italy
Ronald Brand
University Medical Center, Leiden, the Netherlands
Anja van Biezen
Chronic Malignancy WP Registry, Leiden, the Netherlands
Michel Schaap
Radboud University - Nijmegen Medical Centre, Nijmegen, the Netherlands
Peter A. von dem Borne
University Medical Center, Leiden, the Netherlands
Johan Maertens
University Hospital of Leuven, Belgium
Dietrich W. Beelen
University Hospital, Department of Bone Marrow Transplantation, Essen, Germany
Enric Carreras
Hospital Clinic, Barcelona, Spain
Emilio P. Alessandrino
Policlinico San Matteo, Pavia, Italy
Liisa Volin
Helsinki University Central Hospital, Finland
Jürgen H.E. Kuball
University Medical Centre Utrecht, the Netherlands
Angela Figuera
Hospital de la Princesa, Madrid, Spain
Jorge Sierra
Hospital Santa Creu I Sant Pau, Barcelona, Spain
Jürgen Finke
Department of Medicine-Hematology, Oncology, Freiburg, Germany
Nicolaus Kröger
University Hospital Eppendorf, Hamburg, Germany
Theo de Witte
Radboud University - Nijmegen Medical Centre, Nijmegen, the Netherlands
Acquired chromosomal abnormalities are important prognostic factors in patients with myelodysplastic syndromes treated with supportive care and with disease-modifying therapeutic interventions, including allogeneic hematopoietic stem cell transplantation. To assess the prognostic impact of cytogenetic characteristics after hematopoietic stem cell transplantation accurately, we investigated a homogeneous group of 523 patients with primary myelodysplastic syndromes who have received stem cells from human leukocyte antigen-identical siblings. Overall survival at five years from transplantation in good, intermediate, and poor cytogenetic risk groups according to the International Prognostic Scoring System was 48%, 45% and 30%, respectively (P
